Current research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing encouraging results in managing obesity and type 2 disease. Initial information suggest a distinct process contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/